Coeptis Therapeutics Warrants
COEPW
COEPW was delisted on the 24th of April, 2026.
18 hedge funds and large institutions have $286K invested in Coeptis Therapeutics Warrants in 2023 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 4 closing their positions.
5% more capital invested
Capital invested by funds: $272K → $286K (+$14.3K)
14% less funds holding
Funds holding: 21 → 18 (-3)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CF
Cantor Fitzgerald
New York
|
+$13.7K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$12.9K |
| 3 |
ICM
Ionic Capital Management
New York
|
+$12.9K |
| 4 |
RCM
Radcliffe Capital Management
Bala Cynwyd,
Pennsylvania
|
+$4.61K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MC
Meteora Capital
Boca Raton,
Florida
|
-$18.5K |
| 2 |
OCAM
Owl Creek Asset Management
New York
|
-$9.49K |
| 3 |
Walleye Capital
New York
|
-$7.61K |
| 4 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
-$2.23K |
| 5 |
VF
Virtu Financial
New York
|
-$2K |
COEPW Hedge Fund Activity: Q1 2023 in Review
18 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Coeptis Therapeutics Warrants (COEPW) for Q1 2023, worth a combined $286K — up 5.3% from $272K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of COEPW and 2 opened new positions — a net loss of 2 holders — while 4 trimmed existing stakes and 2 added.
The largest buyer was Cantor Fitzgerald, opening a new position worth an estimated $13.7K. The largest seller was Meteora Capital, cutting an estimated $18.5K.
- 18 institutional investors held Coeptis Therapeutics Warrants (COEPW) as of Q1 2023, down from 21 in Q4 2022.
- Funds reported $286K of Coeptis Therapeutics Warrants stock for Q1 2023, up 5.3% quarter-over-quarter.
- 2 funds opened new Coeptis Therapeutics Warrants positions in Q1 2023 and 4 closed out, a net change of -2 holders.
- The largest Coeptis Therapeutics Warrants buyer in Q1 2023 was Cantor Fitzgerald, an estimated $13.7K added.
- The largest Coeptis Therapeutics Warrants seller in Q1 2023 was Meteora Capital, an estimated $18.5K sold.
Based on aggregated 13F filings for Q1 2023.